REG - Oxford BioDynamics - Director/PDMR Shareholding

Oxford BiodynamicsAnnouncement

10/04/2025 16:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250410:nRSJ5753Ea&default-theme=true

RNS Number : 5753E  Oxford BioDynamics PLC  10 April 2025

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

PDMR Dealing

10 April 2025 - Oxford BioDynamics Plc (AIM: OBD) announces that it has
received notice that Non-Executive Director Peter Presland has today purchased
3,398,553 ordinary shares of 0.1 pence each ("Ordinary Shares") at a price of
0.44p per share.

 

Following this transaction, Peter Presland is beneficially interested in a
total of 3,398,553 Ordinary Shares, representing approximately 0.17% of the
Company's current issued share capital.

The notification below, made in accordance with the requirements of UK Market
Abuse Regulation, provides further details:

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Peter Presland
 2   Reason for the notification
 a)  Position/status                                              Director/PDMR
 b)  Initial notification/ Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Oxford BioDynamics Plc
 b)  LEI                                                          2138005Y1TK258O5U928
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of 0.1 pence each

     Identification code

                                                                  ISIN:   GB00BD5H8572
 b)  Nature of the transaction                                    Purchase of Ordinary Shares
 c)  Price(s) and volume(s)

 Price(s)  Volume(s)
                                                                   £0.0044   3,398,553

 

 d)  Aggregated information                                       n/a

     - Aggregated volume

     - Price

 e)  Date of the transaction                                      10 April 2025
 f)  Place of the transaction                                     London Stock Exchange (XLON)

 

 

d)

Aggregated information

- Aggregated volume

- Price

 

n/a

 

e)

Date of the transaction

10 April 2025

f)

Place of the transaction

London Stock Exchange (XLON)

 

-Ends-

For further details please contact:

 Oxford BioDynamics Plc                                              +44 (0)1865 518910

 Iain Ross, Executive Chairman

 Paul Stockdale, CFO

 Shore Capital - Nominated Adviser and Broker                        +44 (0)20 7408 4090

 Advisory: Stephane Auton / Lucy Bowden

 Broking: Fiona Conroy

 WG Partners - Joint Broker                                          +44 (0)20 3705 9330

 David Wilson / Claes Spång / Satheesh Nadarajah / Erland Sternby

 OAK Securities - Joint Broker                                       +44 (0)20 3973 3678

 Jerry Keen / Henry Clarke / Damion Carruel

 Camarco - Financial PR                                              +44 (0)20 3757 4980

 Marc Cohen / Tilly Butcher / Fergus Young                           OBDFinancial@camarco.co.uk

 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjphZTRmOjE1ZmE3ZTA1NmFmMzlmYjIzZmFhOGU1NTc5MWI0OTdiODZmMjVmOTFlOWQ2YjBiZTM3YmNmMTMxMGYxOTcxMjI6cDpU)
 (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjpjZGI4OjQ3ZWJmMjU3YzNhNjYzYzNiYWVjZGNlMTJjZDM5ZGZkYzBlNmQyNTc0OTdlZWU4ZGI4ODFlYzU1OWZmN2JmMWE6cDpU)
 (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer. CiRT is a highly accurate (85%) predictive response test to
immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring of
biomarkers to diagnose patients or determine how individuals might respond to
a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(http://www.oxfordbiodynamics.com) ,  X (@OxBioDynamics) or LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjozM2I4OmVmNzdkN2M0NmYxZDg3ODc0MWQ1NDEyMGQ4MjAxOWVmMTg4ZTMzNWY4MTA5NGE3NTE5ZDdlNWIwNjI5MTRhMTM6cDpU)
.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFIESDIILIE